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Objective: As thoracoscopic lobectomy becomes widely applied for treatment of non–small cell lung cancer,
thoracoscopic segmentectomy remains controversial for patients with small stage I lung cancers. Questions
remain regarding safety, morbidity, mortality, and recurrence rate. This study compared outcomes between thor-
acoscopic segmentectomy and lobectomy.
Methods: Retrospective review was undertaken of patients who underwent thoracoscopic segmentectomy or
lobectomy for clinical stage I non–small cell lung cancer between January 2002 and February 2008. Indications
for segmentectomy were tumor smaller than 3 cm, limited pulmonary reserve, comorbidities, and peripheral
tumor location.
Results: Thirty-one patients underwent segmentectomy and 113 underwent lobectomy. Patients after segmentec-
tomy had worse mean forced expiratory volume in 1 second than after lobectomy (83% vs 92%, P¼ .04). There
were no differences in mean number of nodes (10) and nodal stations (5) resected. Segmentectomy and lobectomy
groups had similar median chest tube durations (2 vs 3 days, P ¼ .18), stays (both 4 days), total complications,
recurrence rates, and survivals at mean follow-ups of 22 and 21 months, respectively. Lobectomy group had 1 30-
day death; segmentectomy group had none. There were 5 (17.2%) recurrences after segmentectomy and 23
(20.4%) after lobectomy (P ¼ .71), with locoregional recurrence rates of 3.5% and 3.6%, respectively.
Conclusion: Thoracoscopic segmentectomy is a safe option for experienced thoracoscopic surgeons treating
patients with small stage I lung cancers. No significant difference in oncologic outcome was seen between thor-
acoscopic segmentectomy and thoracoscopic lobectomy. Lymph node dissection could be performed as effec-
tively during segmentectomy as lobectomy.Lobectomy is the standard surgical treatment for early stage
lung cancer. In 1973, Jensik and colleagues1 published
a study suggesting that segmental resection was equivalent
to lobectomy and represented an adequate operation for
small stage I non–small cell lung cancers (NSCLCs). This
publication started a debate regarding the optimal surgical
approach for early stage NSCLC. Results of a randomized
trial published in 1995 showed that limited pulmonary resec-
tion for stage IA NSCLC did not result in improved morbid-
ity, mortality, or postoperative pulmonary function and was
associated with higher rates of locoregional recurrence and
death relative to lobectomy.2 Lobectomy, however, may
not be the best option for patients with poor cardiopulmo-
nary function. Recently, as a result of an increasing inci-
dence of small lung tumors, there has been renewed
interest in the use of anatomic segmentectomy, especially
for patients unable to tolerate lobectomy because of compro-
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have shown that segmentectomy can be performed safely
without compromising oncologic results.3-7
Advantages of a minimally invasive approach to lobec-
tomy—video-assisted thoracic surgery (VATS) lobec-
tomy—have been previously documented in the literature.
These include decreased postoperative pain, shorter recov-
ery, preserved pulmonary function, decreased inflammatory
response, and improved tolerance of chemotherapy, with
equivalent oncologic outcomes for VATS lobectomy as
for open lobectomy.8-15 VATS lobectomy is becoming the
standard of care.
Despite the growing acceptance of VATS lobectomy,
VATS segmentectomy remains highly controversial as
a choice for treatment of small lung tumors. In addition to
concerns about increased locoregional recurrence, potential
arguments against VATS segmentectomy include higher
rates of complications and inadequate nodal dissection be-
cause of the high complexity of the procedure.5,16 Combining
VATS and limited resection in the form of a VATS segmen-
tectomy, however, may give the benefits of a VATS approach
to patients who need a sublobar resection. To date, only a few
studies have been published investigating the outcomes of
VATS segmentectomy in patients with NSCLC, and these
have generally used a thoracotomy approach for the segmen-
tectomy as their comparison group. There is a lack of pub-
lished studies examining the recurrence rate after VATSrgery c June 2009
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segmentectomy relative to that after VATS lobectomy. This
study examined the role of VATS segmentectomy for treat-
ment of small, early stage NSCLC. We compared morbidity,
recurrence, and survival between patients who underwent
VATS segmentectomy and similarly staged patients who un-
derwent VATS lobectomy.
MATERIALS AND METHODS
From the Lung Cancer Database at the Mount Sinai Medical Center, a ret-
rospective review was conducted of all patients who underwent VATS an-
atomic segmentectomy for clinical stage I NSCLC from January 2002 to
February 2008. Comparison was made with a series of patients who under-
went VATS lobectomy for similarly sized NSCLC. Inpatient and outpatient
charts were reviewed, and information was collected with a standardized
questionnaire. Data included patients’ demographic data, comorbidities, op-
erative and hospital courses, pathologic staging, and postoperative follow-
up. Patients were contacted for additional follow-up information, also
with a standardized questionnaire. Operative mortality was defined as death
during the hospitalization for the pulmonary resection or within 30 days of
the procedure, whichever was longer. Pathologic cancer staging was done in
accordance with the guidelines set forth by the American Joint Committee
on Cancer.
Before surgical resection, all patients underwent preoperative staging
with computed tomographic scanning, with or without positron emission to-
mography, and pulmonary function testing. Additional diagnostic tests were
performed according to patient symptoms and clinical findings. Mediastino-
scopy was not used routinely in the preoperative evaluation of these patients
and was performed only on patients with lymph node enlargement greater
than 1 cm on computed tomographic scan or positive lymph node findings
on positron emission tomographic scan. In cases where mediastinoscopy
was not done, however, ipsilateral thoracoscopic mediastinal node evalua-
tion (N2) was performed at the outset of the lobectomy or segmentectomy.
For patients who were found intraoperatively by frozen-section analysis of
the lymph nodes to have N2 disease, the operation was terminated and in-
duction therapy was carried out. These patients were not included in this
study. Indications for segmentectomy rather than lobectomy were small tu-
mor size (<3 cm), limited pulmonary reserve with extensive comorbidities,
and peripheral location of the tumor.
Bronchoscopy was performed on all patients after intubation and before
repositioning to ensure that the segmental bronchus was free of disease. For
our thoracoscopic approach, three incisions were used. Full description of
this technique has been previously published.10 The avoidance of rib
spreading was critical to the definition of a VATS approach. If rib spreading
was carried out, then the operation was considered a conversion to thoracot-
omy. For a resection to be considered a segmentectomy, individual ligation
of the segmental bronchus and vascular structures was essential. Comple-
tion of the fissure was done with endostaplers after visualization of the
segmental boundaries, and all patients underwent complete hilar and
mediastinal node dissection.
Statistical Analysis
The Student t test and the Wilcoxon test were used for continuous data,
and the c2 test was used for dichotomous data. Disease-free and overall sur-
vivals were estimated with the Kaplan–Meier method. Disease-free survival
was defined as the time from surgery to the first diagnosis of local, regional,The Journal of Thoracic and Caor distant disease recurrence or until the last follow-up. Overall survival was
defined as the time from surgery to death from any cause or last follow-up.
To avoid calculating survival from a small number of observations, data for
survival curves were censored at 48 months for surviving patients. We used
Cox regression analysis to identify predictors of recurrence after resection of
stage I disease. We tested the assumption of proportionality of hazards with
the log–log plotting of survival among appropriate groups. Power calcula-
tion showed that given the 28 events observed in the population, the study
had 80% power to detect whether segmentectomy is associated with at least
a 3.5-times increased hazard of recurrence. The SAS 9.0 statistical package
(SAS Institute, Inc, Cary, NC) was used for all statistical analyses. The in-
stitutional review board of the Mount Sinai School of Medicine approved
this study.
RESULTS
During the stated period, 31 patients underwent VATS
segmentectomy and 113 underwent VATS lobectomy for
similarly sized and staged early stage NSCLC. Patient and
tumor characteristics are summarized in Table 1. The two
groups were similar in age and stage of lung cancer; how-
ever, the results of pulmonary function tests were signifi-
cantly worse in the VATS segmentectomy group than in
the VATS lobectomy group (forced expiratory volume in
1 second 83% vs 92%, P ¼ .04). Also, 61% of patients
in the VATS segmentectomy group had pulmonary comor-
bidities before surgery, and 48% had evidence of significant
cardiovascular disease. At the time of surgery, the average
exposure to smoking in the VATS segmentectomy group
was 47.8 pack-years, versus 34.4 pack-years in the VATS
lobectomy group. Three patients in the VATS segmentec-
tomy group had undergone pulmonary resections on the op-
posite lung within 2 years before the index surgery (2 for
synchronous lesions and 1 for metachronous lesions).
There were 2 patients in VATS segmentectomy group
with stage IIIA disease on the basis of positive mediastinal
nodes found on final pathologic evaluation (level 5 in 1 pa-
tient and level 7 in the other), despite negative results of fro-
zen-section evaluation. Moreover, 1 patient had disease
staged as IIIB because final pathologic examination identi-
fied an unsuspected satellite lesion in the specimen. Mean
tumor size in the VATS segmentectomy group was signifi-
cantly smaller than in the VATS lobectomy group (2.1 vs
2.6 cm, P ¼ .02; Table 1).
The distribution of the segmentectomies performed is
shown in Table 2. Seven patients in VATS segmentectomy
group had mediastinoscopy done, either as a separate proce-
dure or at the same time of the pulmonary resection. There
was no difference in the number of nodes or the number of
nodal stations resected. Both groups of patients on average
underwent dissection of 5 nodal stations, resulting in an av-
erage of 10 lymph nodes available for pathologic evaluation
and staging. Six patients in the VATS segmentectomy group
underwent additional wedge resections for benign lesions as
part of the procedure, and 1 patient underwent extended seg-
mentectomy because of proximity of the tumor to the edge of
the segment. There were 4 conversions to minithoracotomyrdiovascular Surgery c Volume 137, Number 6 1389
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atomic considerations). In the patient with intraoperative
bleeding, hemostasis was achieved with a sponge stick be-
fore conversion to a minithoracotomy. One unit of blood
was given to this patient during the surgery; however, he
did not have any intraoperative hemodynamic instability.
Postoperative recovery and follow-up results were similar
between the groups. Chest tube duration, hospital stay, and
number of complications did not differ between the groups
(Table 3). Specific complications after each procedure are
listed in Table 4. There was 1 death within 30 days recorded
in the VATS lobectomy group, with none in VATS segmen-
tectomy group (Table 3). There were no differences in the
overall and site-specific rates of recurrence. The locore-
gional recurrence rate was low in both groups, with 1 case
(3.5%) in the VATS segmentectomy group and 4 (3.6%)
in the VATS lobectomy group. Overall and disease-free
survivals were also similar between the groups (Table 3,
Figure 1). Multivariate analysis also showed no significant
difference in rate of recurrence between two types of resec-
tion (Table 5). To adjust for difference in tumor size in our
TABLE 1. Demographic and clinical patient characteristics
Variable
Segmentectomy
(n ¼ 31)
Lobectomy
(n ¼ 113)
P
value
Age, years (mean  SD) 65  9.5 69  10.6 .11
Sex (male/female) 8:23 54:59 .03
Forced expiratory volume in
1 s (%, mean  SD)
83  22.0 92  20.1 .04
Tumor size (cm, mean  SD) 2.1  0.9 2.6  1.2 .02
Histologic type (No.) .003
Adenocarcinoma 19 (61.3%) 88 (77.9%)
Squamous cell 3 (9.7%) 17 (15.0%)
Other 7 (22.6%) 8 (7.1%)
Hamartoma 2 (6.4%) 0
Stage* (No.) .37
IA 20 (69.0%) 66 (58.4%)
IB 5 (17.2%) 34 (30.1%)
IIA 1 (3.5%) 4 (3.5%)
IIB 0 4 (3.5%)
III or IV 3 (10.3%) 5 (4.5%)
*Among patients treated for clinical stage I non–small cell lung cancer, n¼ 29 for seg-
mentectomy and n ¼ 113 for lobectomy.
TABLE 2. Type of segmental resection by anatomic location
No. %
Lingulectomy 2 6.5%
Left LL superior segmentectomy 3 9.7%
Lingula-sparing upper lobectomy 17 54.8%
Right LL superior segmentectomy 7 22.6%
Left LL composite basilar segmentectomy 1 3.2%
Right LL composite basilar segmentectomy 1 3.2%
Total 31 100%
LL, Lower lobe.1390 The Journal of Thoracic and Cardiovascular Sugroups, the analysis was repeated for patients with only stage
IA cancer (mean tumor size in VATS segmentectomy and
VATS lobectomy groups 1.7 cm and 1.8 cm, respectively);
this analysis also did not show any significant difference be-
tween the two types of resection (P ¼ .850).
The impact of size of tumor in patients with stage I
NSCLC on recurrence after VATS segmentectomy was an-
alyzed as well. Figure 2 shows a trend toward increased re-
currence among patients with tumors larger than 2 cm, but
this trend did not reach statistical significance (P ¼ .33).
DISCUSSION
Our study analyzed the postoperative outcomes of pa-
tients undergoing a VATS segmentectomy. It is the only
study to date to compare morbidity, recurrence, and survival
data between patients undergoing VATS segmentectomy
and VATS lobectomy. We have demonstrated that VATS
segmentectomy can be performed safely with excellent
TABLE 3. Recovery and follow-up
Variable
Segmentectomy
(n ¼ 31)
Lobectomy
(n ¼ 113)
P
value
Mean follow-up (mo, mean  SD) 22  16.6) 21  12.6) .83
Chest tube duration (d, median
and range)
2 (1-33) 3 (2-35) .18
Stay (d, median and range) 4 (1-98) 4 (3-34) .10
Complications (No.) 8 (25.8%) 30 (26.6%) .82
Major 3 (9.7%) 7 (6.2%)
Minor 5 (16.1%) 23 (20.4%)
Perioperative death (30–d, No.) 0 1
Recurrence* (No.) 5 (17.2%) 23 (20.4%) .71
Locoregional 1 (3.5%) 4 (3.6%)
Distant 3 (10.3%) 13 (11.5%)
Both 1 (3.5%) 5 (5.3%)
*Among patients treated for clinical stage I non–small cell lung cancer, n ¼ 29 for
segmentectomy and n ¼ 113 for lobectomy.
TABLE 4. Postoperative complications
Segmentectomy Lobectomy
Complication No. % No. %
Atrial fibrillation* 0% 0% 12% 10.6%
Effusiony 1 3.2% 0% 0%
Empyemaz 0 0% 2% 1.8%
Respiratory failurex 2 6.5% 1% 0.9%
Vocal cord paralysis 0 0% 1% 0.9%
Air leak (>5 d) 4 12.9% 11% 9.7%
Pneumonia 1 3.2% 1% 0.9%
Clostridium difficile 0 0% 1% 0.9%
Death 0 0% 1% 0.9%
Total 8 25.8% 30% 26.6%
*New-onset atrial fibrillation; 2 patients required electrical cardioversion. yEffusion
necessitating chest tube reinsertion. zEmpyema necessitating reoperation.
xRespiratory failure requiring reintubation.rgery c June 2009
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to our results for VATS lobectomy in patients with small,
early stage NSCLC.
The perceived complexity of segmentectomy relative to
lobectomy and concerns regarding increased morbidity re-
lated to prolonged air leak and local recurrence rates have
deterred most surgeons from using this approach for early
stage lung cancer. Combining thoracoscopy and segmentec-
tomy potentially increases these risks by increasing the com-
plexity of the operation. Since 1973, when the first study was
published suggesting that segmental resection was equiva-
lent to lobectomy and therefore an adequate operation for
stage I NSCLC,1 sublobar resection has been the topic of ex-
tensive debate. Some published studies have argued against
segmentectomy as a procedure for early lung cancer.2,16,17
Ginsberg and colleagues2 published results showing the
local recurrence rate to be 3 times higher after limited resec-
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FIGURE 1. Survivals according to type of resection in patients with path-
ologic stage I non–small cell cancer, video-assisted thoracoscopic surgery
segmentectomy (VATS Segmentectomy) versus video-assisted thoraco-
scopic surgery (VATS lobectomy). A, Overall survival; B, disease-free sur-
vival.The Journal of Thoracic and Ction than after lobectomy in patients with stage I NSCLC,
with a resultant 30% increase in overall death rate. This
study has been criticized for including about a third of
patients with nonanatomic wedge resections in the limited
resection group. Since then, numerous published studies
have suggested that nonanatomic wedge resections result
in higher rates of locoregional recurrence and worse can-
cer-related survival than anatomic resections,18,19 Thus
combining patients undergoing wedge resection and with
those undergoing segmentectomy potentially obscured any
benefit limited to the patients undergoing segmentectomy.
In our study, patients undergoing VATS segmentectomy
were discharged after stays similar in length to those of
TABLE 5. Multivariate analysis of factors predicting recurrence
Among patients with stage I non–small cell lung cancer
Variable Hazard ratio
95% Confidence
interval
P
value
Type of resection
Lobectomy Reference — —
Segmentectomy 0.85 0.21–3.51 .82
Age 0.96 0.91–1.01 .08
Sex
Female Reference — —
Male 1.06 0.42–2.71 .90
Tumor size 1.21 0.75–1.97 .43
Histologic type
Adenocarcinoma Reference — —
Squamous cell carcinoma 0.23 0.04–1.17 .08
Other 2.12 0.55–8.14 .28
No. nodal stations sampled 0.76 0.45–1.28 .30
No. lymph nodes sampled 1.07 0.95–1.20 .25
T classification
T1 Reference — —
T2 4.49 1.36–14.90 .01
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FIGURE 2. Disease-free survival in patients with pathologic stage I non–
small cell cancer after video-assisted thoracoscopic surgery segmentectomy
according to tumor size: 2 cm or smaller versus larger than 2 cm.ardiovascular Surgery c Volume 137, Number 6 1391
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tients in the VATS segmentectomy group had significantly
worse pulmonary function before surgery. The median chest
tube duration of 2 days and hospital stay of 4 days in our
VATS segmentectomy group compares favorably with pre-
viously published results.3,7,14,20,21 Our results revealed
a trend toward earlier chest tube removal after VATS seg-
mentectomy but did not demonstrate any significant differ-
ences in chest tube duration and hospital stay between the
groups. Furthermore, patients in both groups showed similar
complication rates (VATS segmentectomy 25.8%, VATS
lobectomy 26.6%). These rates are comparable to those in
previously published reports, in which the average rates of
complication are 17.6% to 31.3% after VATS segmentec-
tomy, 32% to 39% after open segmentectomy, and
15.3% to 23.8% after VATS resection.8,14,20-22 There
were 4 patients in our VATS segmentectomy group who un-
derwent conversion to minithoracotomy, with only 1 of
these conversions occurring as a result of bleeding. Two
of the conversions occurred during the first 2 years of our
6-year experience, underscoring that VATS segmentectomy
is a technically challenging procedure requiring a certain
level of technical expertise in thoracoscopic procedures.
In the last decade, a growing number of published studies
have demonstrated that segmental resections achieve compa-
rable oncologic and survival outcomes to lobectomy.3-7,21
Schuchert and colleagues3 published results of 182 seg-
mentectomies (done with thoracotomy and VATS) and 246
lobectomies in patients with NSCLC stage IA and IB. Similar
overall recurrence rates were observed after segmentectomy
(17.6%) and lobectomy (16.7%). There was also no differ-
ence in overall survival between the two groups.3
Our recurrence rates and mortalities are consistent with
previously published data. Our overall recurrence rate in
the VATS segmentectomy group was 17.2%, versus
20.4% in the VATS lobectomy group. Furthermore, the lo-
coregional recurrence rates were very low in our patients,
3.5% and 3.6% for VATS segmentectomy and VATS lo-
bectomy respectively. The results of this study and the de-
scribed recent studies suggest that at least for current
tumors, which may be smaller and of a different histologic
type than in earlier eras, thoracoscopic segmentectomy
may be an acceptable operation from an oncologic stand-
point.
Recently, more evidence has been published to suggest
that tumor size plays an important role in recurrence among
patients undergoing segmentectomy for early stage lung
cancer.3-6,16 Okumura and colleagues4 reported a significant
difference in survival among patients with T1N0M0 disease
when tumor size exceeded 2 cm, with 5-year survivals of
58% after segmentectomy and 78% after lobectomy.4 Schu-
chert and colleagues,3 however, have suggested that the ratio
of margin to tumor is more important as a risk factor for1392 The Journal of Thoracic and Cardiovascular Surecurrence than the size of the tumor alone. In their study,
ratios of margin to tumor less than 1 are associated with
a higher rate of recurrence. It becomes more difficult to
maintain an adequate tumor-free margin as tumors get
larger, which may help to explain the observation of a higher
rate of recurrence among patients with larger lesions. We
were unable to demonstrate a significant difference in recur-
rence rate for larger tumors. When we compared disease-free
survival after VATS segmentectomy between patients with
tumors 2 cm or smaller and those with tumors larger than
2 cm, however, there was a trend toward decreased recur-
rence among patients with smaller lesions (Figure 2).
We have also demonstrated that an adequate lymph node
dissection, which is important for proper staging and possibly
survival, can be performed during VATS segmentectomy.
The importance of an adequate assessment of pulmonary
lymph nodes in patients with NSCLC is also supported by
previously published studies.17,23-26
Moreover, as many as 11.5% of patients undergoing sur-
gery for lung cancer have additional primary cancers de-
velop within their lifetimes and thus require additional
resection.17 Limited pulmonary resection allows future re-
sections through the preservation of lung volume.
Because this was a retrospective study, the selection of pa-
tients was not random, which may have introduced a bias in
the selection of a patient for a given procedure. Because
VATS segmentectomy is not frequently done, the study
had a low power to detect all clinically significant differ-
ences in recurrence between the two groups. The sparse
data should be further assessed in future studies. The study
being conducted by the Cancer and Leukemia Group B
(CALGB 140503) should further elucidate the role of seg-
mentectomy for patients with NSCLC 2 cm or smaller. It
randomly assigns patients to undergo segmentectomy or
wedge resection and lobectomy, with the access technique
selected by the surgeon (VATS or thoracotomy).
In conclusion, this study suggests that thoracoscopic seg-
mentectomy is a safe option for experienced thoracoscopic
surgeons who are treating patients with small stage I lung
cancers. In this retrospective study, there was no significant
difference detected in oncologic outcome between VATS
segmentectomy and VATS lobectomy groups. Furthermore,
the lymph node dissection could be performed as effectively
during VATS segmentectomy as during a VATS lobectomy.
With experience, minimally invasive strategies can be ap-
plied to ever more challenging operations, such as pulmo-
nary segmentectomy.
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